Robert Chess Sells 2,940 Shares of Twist Bioscience Co. (NASDAQ:TWST) Stock

Twist Bioscience Co. (NASDAQ:TWST) Director Robert Chess sold 2,940 shares of the company’s stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $53.13, for a total value of $156,202.20. Following the transaction, the director now directly owns 18,173 shares of the company’s stock, valued at $965,531.49. This represents a 13.93 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Robert Chess also recently made the following trade(s):

• On Tuesday, January 7th, Robert Chess sold 5,000 shares of Twist Bioscience stock. The shares were sold at an average price of $50.00, for a total transaction of $250,000.00.
• On Thursday, December 5th, Robert Chess sold 3,504 shares of Twist Bioscience stock. The shares were sold at an average price of $51.85, for a total transaction of $181,682.40.

Twist Bioscience Price Performance

NASDAQ TWST opened at $45.37 on Thursday. The company has a quick ratio of 4.54, a current ratio of 4.96 and a debt-to-equity ratio of 0.03. The company has a market cap of $2.71 billion, a PE ratio of -13.42 and a beta of 1.87. Twist Bioscience Co. has a 52 week low of $27.41 and a 52 week high of $60.90. The firm’s 50-day simple moving average is $48.64 and its two-hundred day simple moving average is $45.98.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Monday, February 3rd. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.09. Twist Bioscience had a negative net margin of 59.76% and a negative return on equity of 32.69%. The company had revenue of $88.70 million during the quarter, compared to the consensus estimate of $86.96 million. During the same period last year, the firm earned ($0.75) EPS. Twist Bioscience’s revenue for the quarter was up 24.1% on a year-over-year basis. Research analysts predict that Twist Bioscience Co. will post -2.12 earnings per share for the current year.

Institutional Trading of Twist Bioscience

Institutional investors have recently added to or reduced their stakes in the stock. Wilmington Savings Fund Society FSB purchased a new stake in shares of Twist Bioscience in the third quarter worth about $34,000. Van ECK Associates Corp lifted its stake in Twist Bioscience by 56.4% in the 4th quarter. Van ECK Associates Corp now owns 740 shares of the company’s stock worth $34,000 after purchasing an additional 267 shares in the last quarter. Signaturefd LLC boosted its holdings in Twist Bioscience by 63.0% in the 3rd quarter. Signaturefd LLC now owns 792 shares of the company’s stock valued at $36,000 after purchasing an additional 306 shares during the period. US Bancorp DE grew its position in shares of Twist Bioscience by 72.0% during the 4th quarter. US Bancorp DE now owns 1,436 shares of the company’s stock valued at $67,000 after purchasing an additional 601 shares in the last quarter. Finally, Beaird Harris Wealth Management LLC purchased a new position in shares of Twist Bioscience during the 3rd quarter valued at $95,000.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on TWST shares. Robert W. Baird boosted their price target on Twist Bioscience from $48.00 to $54.00 and gave the company an “outperform” rating in a research note on Tuesday, February 4th. Wolfe Research assumed coverage on shares of Twist Bioscience in a research note on Friday, December 13th. They issued an “outperform” rating and a $60.00 price objective for the company. Barclays cut their price target on Twist Bioscience from $55.00 to $52.00 and set an “overweight” rating on the stock in a research note on Tuesday, November 19th. Leerink Partners raised their target price on Twist Bioscience from $45.00 to $48.00 and gave the stock a “market perform” rating in a research report on Thursday, October 17th. Finally, TD Cowen restated a “buy” rating and issued a $58.00 price target on shares of Twist Bioscience in a research report on Tuesday, November 26th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Twist Bioscience presently has a consensus rating of “Moderate Buy” and an average price target of $53.80.

About Twist Bioscience

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.